The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
A | Alimentary tract and metabolism | |
2
|
A12 | Mineral supplements | |
3
|
A12B | Potassium | |
4
|
A12BA | Potassium |
| Code | Title | |
|---|---|---|
| A12BA01 | Potassium chloride | |
| A12BA02 | Potassium citrate | |
| A12BA03 | Potassium hydrogentartrate | |
| A12BA04 | Potassium hydrogencarbonate | |
| A12BA05 | Potassium gluconate | |
| A12BA30 | Combinations | |
| A12BA51 | Potassium, combinations |
| Active Ingredient |
|---|
|
|
|
Potassium plays a vital physiological role in maintenance of normal electrical excitability of nerve and muscle. It is also important in the genesis and correction of imbalances of acid-base metabolism. |
|
Citrate and citric acid solutions are systematic and urinary alkalinizers thereby providing symptomatic relief of dysuria. |
|
|
|
|
|
|
|
|
| Document | Type | Information Source | |
|---|---|---|---|
| CYSTOPURIN Granules for oral solution | MPI, EU: SmPC | Health Products Regulatory Authority (IE) | |
| K-TAB Film-coated tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| KLOR-CON Extended-release tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| KLOR-CON Powder for oral solution | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| SLOW K Coated tablet | MPI, EU: SmPC | Health Products Regulatory Authority (IE) | |
| UROCIT-K Tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) |